Literature DB >> 17724066

Anthrax protective antigen cleavage and clearance from the blood of mice and rats.

Mahtab Moayeri1, Jason F Wiggins, Stephen H Leppla.   

Abstract

Bacillus anthracis protective antigen (PA) is an 83-kDa (PA83) protein that is cleaved to the 63-kDa protein (PA63) as an essential step in binding and internalizing lethal factor (LF). To assess in vivo receptor saturating PA concentrations, we injected mice with PA variants and measured the PA remaining in the blood at various times using PA83- and PA63-specific enzyme-linked immunosorbent assays. We found that both wild-type PA (WT-PA) and a receptor-binding-defective mutant (Ub-PA) were cleaved to PA63 independent of their ability to bind cells. This suggested a PA-acting protease activity in the blood. The protease cleaved PA at the furin cleavage sequence because furin site-modified PA mutants were not cleaved. Cleavage measured in vitro was leupeptin sensitive and dependent on calcium. Cell surface cleavage was important for toxin clearance, however, as Ub-PA and uncleavable PA mutants were cleared at slower rates than WT-PA. The cell binding-independent cleavage of PA was also verified by using Ub-PA (which is still cleaved) to rescue mice from toxin challenge by competitively binding circulating LF. This mutant was able to rescue mice even when given 12 h before toxin challenge. Its therapeutic ability was comparable to that of dominant-negative PA, which binds cells but does not allow LF translocation, and to the protection afforded through receptor clearance by WT-PA and uncleavable receptor binding-competent mutants. The PA cleavage and clearance observed in mice did not appear to have a role in the differential mouse susceptibility as it occurred similarly in lethal toxin (LT)-resistant DBA/2J and LT-sensitive BALB/cJ mice. Interestingly, PA63 was not found in LT-resistant or -sensitive rats and PA83 clearance was slower in rats than in mice. Finally, to determine the minimum amount of PA required in circulation for LT toxicity in mice, we administered time-separated injections of PA and LF and showed that lethality of LF for mice after PA was no longer measurable in circulation, suggesting active PA sequestration at tissue surfaces.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724066      PMCID: PMC2168306          DOI: 10.1128/IAI.00719-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax.

Authors:  B R Sellman; M Mourez; R J Collier
Journal:  Science       Date:  2001-04-27       Impact factor: 47.728

2.  Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.

Authors:  S Liu; T H Bugge; S H Leppla
Journal:  J Biol Chem       Date:  2001-03-12       Impact factor: 5.157

3.  Optimized production and purification of Bacillus anthracis lethal factor.

Authors:  S Park; S H Leppla
Journal:  Protein Expr Purif       Date:  2000-04       Impact factor: 1.650

4.  Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor.

Authors:  Heather M Scobie; G Jonah A Rainey; Kenneth A Bradley; John A T Young
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-16       Impact factor: 11.205

5.  Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin.

Authors:  S Liu; S Netzel-Arnett; H Birkedal-Hansen; S H Leppla
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

6.  Identification of the cellular receptor for anthrax toxin.

Authors:  K A Bradley; J Mogridge; M Mourez; R J Collier; J A Young
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

7.  Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody.

Authors:  M J Rosovitz; Peter Schuck; Mini Varughese; Arun P Chopra; Varsha Mehra; Yogendra Singh; Lisa M McGinnis; Stephen H Leppla
Journal:  J Biol Chem       Date:  2003-05-27       Impact factor: 5.157

8.  Potent antitumor activity of a urokinase-activated engineered anthrax toxin.

Authors:  Shihui Liu; Hannah Aaronson; David J Mitola; Stephen H Leppla; Thomas H Bugge
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-13       Impact factor: 11.205

9.  Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice.

Authors:  Mahtab Moayeri; Diana Haines; Howard A Young; Stephen H Leppla
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

10.  Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process.

Authors:  Laurence Abrami; Shihui Liu; Pierre Cosson; Stephen H Leppla; F Gisou van der Goot
Journal:  J Cell Biol       Date:  2003-01-27       Impact factor: 10.539

View more
  42 in total

Review 1.  Anthrax lethal and edema toxins in anthrax pathogenesis.

Authors:  Shihui Liu; Mahtab Moayeri; Stephen H Leppla
Journal:  Trends Microbiol       Date:  2014-03-27       Impact factor: 17.079

2.  Detection of anthrax protective antigen (PA) using europium labeled anti-PA monoclonal antibody and time-resolved fluorescence.

Authors:  Robyn A Stoddard; Conrad P Quinn; Jarad M Schiffer; Anne E Boyer; Jason Goldstein; Dennis A Bagarozzi; Stephen D Soroka; Leslie A Dauphin; Alex R Hoffmaster
Journal:  J Immunol Methods       Date:  2014-05-22       Impact factor: 2.303

Review 3.  Membrane translocation by anthrax toxin.

Authors:  R John Collier
Journal:  Mol Aspects Med       Date:  2009-06-27

4.  A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.

Authors:  Mahtab Moayeri; Clinton E Leysath; Jacqueline M Tremblay; Catherine Vrentas; Devorah Crown; Stephen H Leppla; Charles B Shoemaker
Journal:  J Biol Chem       Date:  2015-01-06       Impact factor: 5.157

5.  Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen.

Authors:  L K Petersen; Y Phanse; A E Ramer-Tait; M J Wannemuehler; B Narasimhan
Journal:  Mol Pharm       Date:  2012-03-20       Impact factor: 4.939

6.  Role of the protective antigen octamer in the molecular mechanism of anthrax lethal toxin stabilization in plasma.

Authors:  Alexander F Kintzer; Harry J Sterling; Iok I Tang; Ali Abdul-Gader; Andrew J Miles; B A Wallace; Evan R Williams; Bryan A Krantz
Journal:  J Mol Biol       Date:  2010-04-28       Impact factor: 5.469

7.  Binding and cell intoxication studies of anthrax lethal toxin.

Authors:  Momchilo Vuyisich; Claire K Sanders; Steven W Graves
Journal:  Mol Biol Rep       Date:  2012-01-05       Impact factor: 2.316

8.  Domain specificity of the human antibody response to Bacillus anthracis protective antigen.

Authors:  Donald C Reason; Anuska Ullal; Justine Liberato; Jinying Sun; Wendy Keitel; Jianhui Zhou
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

9.  Anthrax toxin triggers the activation of src-like kinases to mediate its own uptake.

Authors:  Laurence Abrami; Béatrice Kunz; F Gisou van der Goot
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

10.  Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies.

Authors:  Nareen Abboud; Magdia De Jesus; Antonio Nakouzi; Radames J B Cordero; Mario Pujato; András Fiser; Johanna Rivera; Arturo Casadevall
Journal:  J Biol Chem       Date:  2009-07-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.